A biotech superstar with UNTHSC roots
By Jan Jarvis
Six years ago in an acceleration lab at UNT Health Science Center, the co-founders of ZS Pharma were developing a drug that they believed held great promise. But even with such lofty expectations, ZS Pharma co-founders Alvaro Guillem and Jeff Keyser may have underestimated their biotech startup’s potential.
Earlier this month British drug maker AstraZeneca agreed to acquire ZS Pharma for $2.7 billion in cash.
In the pharmaceutical world – where it typically takes a decade or more to move a drug from bench to bedside – ZS Pharma has moved at lightning speed. UNT Health Science Center helped make it all possible by providing offices, conference rooms and a lab where much of the work was done, Guillem said.
“During the early years it was critical to have the support of institutions like UNTHSC and the accelerator labs to be able to move the project forward,” Guillem said. “To this day, we continue to collaborate with labs and rely on their equipment and expertise to address various technical topics.”
From the start, ZS Pharma had all the making of a biotech superstar. Founded in 2008, it debuted on Wall Street as the first biotech IPO in Texas since 2000. Its drug, called ZS-9, has been on the fast track from the start.
Multiple clinical trials have shown the effectiveness of the drug, which is expected to hit the market in 2016. It treats hyperkalemia, a potentially life-threatening disease caused by excess potassium. About one in 200,000 people have the condition, which often affects people with chronic kidney disease and chronic heart failure.
Since 2006, UNT Health Science Center’s Office of Research Development and Commercialization and TECH Fort Worth, a non-profit technology incubator, have worked in partnership to bring new technologies to the market.
Firms get a boost from the UNTHSC Accelerator Lab Program along with the Executives-in-Residence, who act as mentors and offer advice from their years of experience in the pharmaceutical industry.
Taking research to the marketplace can be an arduous process. Playing a part in getting this drug on the path to patients has been rewarding for everyone involved , said Lawrence “Joe” Allred, Associate Vice President for Research and Innovation at UNTHSC.
“We can rightfully take pride in ZS Pharma’s success as a graduation of incubation in our Accelerator Labs,” he said.
By Alli Haltom Evonne Kaplan-Liss was struggling with the effects of ulcerative colitis, recovering from surgery and feeling hopeless. “I sank into a deep depression,” said Kaplan-Liss, now a physician and Assistant Dean of Narrative Reflection and Patient Communication for the T...Read more
Apr 23, 2018
By Jeff Carlton The databases of the National Missing and Unidentified Persons System (NamUs) contain files on more than 1,000 active missing person cases in Texas and about 14,000 nationwide – each one a tragedy for the families involved. “I’m not sure we can help a family fin...Read more
Apr 18, 2018
By Alex Branch Rita Patterson, PhD, a UNT Health Science Center Professor, has been inducted into the American Institute for Medical and Biological Engineering College of Fellows, one of the highest professional distinctions for medical and biological engineers. Dr. Patterson was rec...Read more
Apr 16, 2018
By Raul Vintimilla, Department of Pharmacology and Neuroscience I had earned my medical degree and finished a three-year hospital residency in Cuenca, Ecuador when I decided to move my family to the United States. I had discovered during my training that clinical care was not my pass...Read more
Apr 11, 2018